Ryanodex

Malignant Hyperthermia, Muscle Spasticity, Malignant Hyperthermia + 4 more
Treatment
20 Active Studies for Ryanodex

What is Ryanodex

DantroleneThe Generic name of this drug
Treatment SummaryDantrolene is a medicine that does not work the same way as other drugs in its class, such as phenytoin. It is made from a chemical called a hydantoin derivative.
Dantrolene Sodiumis the brand name
Ryanodex Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dantrolene Sodium
Dantrolene
2005
36

Effectiveness

How Ryanodex Affects PatientsDantrolene is a medicine that helps relax the muscles. It is the only treatment for a dangerous condition called malignant hyperthermia. It works by interfering with the release of calcium from the muscles, which helps restore normal levels of calcium in the cells. In malignant hyperthermia, it is believed that certain drugs (like general anesthetics and muscle relaxants) cause an increase in calcium levels in the muscle cells, which can lead to a dangerous situation. Dantrolene helps bring the calcium levels back to normal.
How Ryanodex works in the bodyDantrolene works on muscle cells to prevent them from contracting. It does this by binding to a receptor in the muscle, which stops calcium from being released. Calcium is needed for muscles to contract, so without it, the muscle cannot move.

When to interrupt dosage

The optimal dose of Ryanodex is contingent upon the diagnosed condition, including Stroke, Spasticity and Spinal Cord Injury. The amount of dosage is reliant on the mode of delivery (e.g. Capsule - Oral or Injection, Solution - Intravenous) featured in the table underneath.
Condition
Dosage
Administration
Malignant Hyperthermia
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Malignant Hyperthermia
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Multiple Sclerosis
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Stroke
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Spinal Cord Injury
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Cerebral Palsy
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Muscle Spasticity
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous

Warnings

Ryanodex has six contraindications, so it should not be employed in combination with the conditions presented in the below table.Ryanodex Contraindications
Condition
Risk Level
Notes
Muscle Spasticity
Do Not Combine
Muscle Spasticity
Do Not Combine
Cirrhosis
Do Not Combine
Hepatitis
Do Not Combine
Locomotion
Do Not Combine
Liver Diseases
Do Not Combine
There are 20 known major drug interactions with Ryanodex.
Common Ryanodex Drug Interactions
Drug Name
Risk Level
Description
Agmatine
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Agmatine.
Amiodarone
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Amiodarone.
Amlodipine
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Amlodipine.
Aranidipine
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Aranidipine.
Azelastine
Major
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ryanodex Toxicity & Overdose RiskThe toxic dose of this drug in rats is 7400mg/kg. Signs of an overdose include muscle weakness, confusion, vomiting, diarrhea, and the presence of crystals in the urine.

Ryanodex Novel Uses: Which Conditions Have a Clinical Trial Featuring Ryanodex?

258 active clinical trials are examining the possible benefits of Ryanodex in treating Multiple Sclerosis, Spinal Cord Injury and Spasticity-related conditions.
Condition
Clinical Trials
Trial Phases
Muscle Spasticity
0 Actively Recruiting
Multiple Sclerosis
127 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Malignant Hyperthermia
0 Actively Recruiting
Malignant Hyperthermia
0 Actively Recruiting
Cerebral Palsy
0 Actively Recruiting
Stroke
6 Actively Recruiting
Not Applicable, Phase 1
Spinal Cord Injury
68 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 1

Patient Q&A Section about ryanodex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do you administer RYANODEX?

"The recommended dosage of RYANODEX® for adults and children is 1 mg/kg, given as an intravenous push. If the person continues to have physiologic and metabolic abnormalities associated with MH, additional intravenous doses up to a maximum of 10 mg/kg may be given."

Answered by AI

Is RYANODEX the same as dantrolene?

"RYANODEX® uses a unique technology that helps it to address deficiencies that other dantrolene sodium products have."

Answered by AI

What is RYANODEX used for?

"The drug RYANODEX® is indicated for the treatment of a condition called malignant hyperthermia. This condition is treated by using appropriate supportive measures in addition to the drug. RYANODEX® is also indicated for the prevention of malignant hyperthermia in patients who are at a high risk for developing the condition."

Answered by AI

What do you mix RYANODEX with?

"What is the process for reconstituting RYANODEX®?

To reconstitute RYANODEX®, add 5 mL of sterile water for injection to the vial. Shake the vial until the RYANODEX® is mixed thoroughly (should take less than 10 seconds)."

Answered by AI

Clinical Trials for Ryanodex

Image of Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo in Buffalo, United States.

Mindset Training for MS

18 - 65
All Sexes
Buffalo, NY
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation. Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account. In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved. This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).
Recruiting
1 Prior Treatment
Jacobs School of Medicine and Biomedical Sciences, Neurology, University at BuffaloHanneke E Hulst, Prof
Have you considered Ryanodex clinical trials? We made a collection of clinical trials featuring Ryanodex, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Have you considered Ryanodex clinical trials? We made a collection of clinical trials featuring Ryanodex, we think they might fit your search criteria.Go to Trials
Image of Cognixion HQ in Santa Barbara, United States.

Cognixion + Apple Vision Pro for ALS

18+
All Sexes
Santa Barbara, CA
The goal of this study is refine the usability of a BCI capable communication platform. The study will take place in the United States area and will enroll up to 10 participants with late stage ALS, traumatic brain injury (TBI) or spinal cord injury (SCI) that have assistive communication and computer control needs. Each subject will receive an integrated Cognixion + Apple Vision Pro device that includes an augmented reality brain computer interface and associated communication software. The study duration is 3-4 months for each participant. The key questions that will be addressed in this study are: 1. Identify the ability of individuals with target indications to use the integrated Cognixion-Apple Vision Pro system to communicate effectively. 2. Identify the ability of such individuals to learn to use BCI, ET-BCI and other modalities, and to measure their progress over time. 3. Identify the effectiveness of the different forms of input supported by the combined Cognixion-Apple Vision Pro system (BCI, eye-tracking) in allowing such individuals to communicate and have agency. 4. Identify how input such as BCI can be optimized to suit the needs of individuals (e.g., specific frequencies that work best for an individual, SNR with different frequencies, number of targets, length of recording for each frequency) and improve overall usability. 5. Identify the extent to which personalization through a large language model (LLM) affects communication. 6. Identify the appropriate capabilities to enable through an agentic communication interface. Key measures include: ITR - information transfer rate SUS - system usability scale
Waitlist Available
Has No Placebo
Cognixion HQChristopher J UllrichCognixion
Image of John D. Dingell VA Medical Center in Detroit, United States.

Ocrelizumab for Multiple Sclerosis

18 - 75
All Sexes
Detroit, MI
This study seeks to assess the effects of long-term ocrelizumab therapy on fatigue (extreme tiredness) as well as cognition (thinking and reasoning skills, such as memory, learning and attention), in veterans with multiple sclerosis. The evaluation will involve cognitive assessment scales (to assess memory, attention and learning abilities), clinical evaluations (to assess nerve function and ability to move), and patient-reported outcome measures (in which you will answer questions about your tiredness, sleep and how you function in daily life). These assessments will occur at baseline (visit 1), 6 month (Visit-2) and 12 months (visit 3) to track changes over time.
Waitlist Available
Has No Placebo
John D. Dingell VA Medical CenterGenentech, Inc.
Image of Medical University of South Carolina in Charleston, United States.

Motor Evoked Potential Conditioning for Spinal Cord Injury

18+
All Sexes
Charleston, SC
The purpose of this research study is to examine the effect of a brain stimulation training to improve the function of brain-spinal cord- muscle connections. Because brain-to-muscle pathways are very important in our movement control, restoring function of these pathways may improve movement problems after injuries. Spinal cord injury causes damage to the brain-to-muscle connection. However, when the injury is "incomplete", there is a possibility that some of the brain-to-muscle pathways are still connected and may be trained to improve movement function. For examining brain-to-muscle pathways, investigators use a transcranial magnetic stimulator. Investigators hope that the results of this research study will help us develop new treatments for people who have movement disabilities. This study will require about 42 visits over the first 14 weeks, and another 6 visits over an additional 3 months. Each visit will take about 1 ½ hours.
Recruiting
Has No Placebo
Medical University of South CarolinaAiko Thompson, PhD
Have you considered Ryanodex clinical trials? We made a collection of clinical trials featuring Ryanodex, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security